Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin

Healthy Clinical Trial

Official title:

A Phase 1, Single-Dose, Open-Label Study to Characterize and Compare the Pharmacokinetics, Safety, and Effect on QTc Interval of AG-348 in Healthy Subjects of Japanese Origin and Healthy Subjects of Non-Asian Origin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03250598
• Other study ID #: AG348-C-004
• Status: Completed
• Phase: Phase 1
• First received: August 11, 2017
• Last updated: October 17, 2017
• Start date: August 9, 2017
• Est. completion date: October 9, 2017

Study information

• Verified date: October 2017
• Source: Agios Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this Phase I, single-dose, open-label trial is to evaluate the pharmacokinetics, safety, and effect on QTc interval of AG-348 in healthy, adult Japanese and Non-Asian subjects. The study plans to evaluate 3 cohorts of a single oral dose of AG-348 in Japanese and Non-Asian subjects. Pharmacokinetic sampling will take place serially at specified times during conduct of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: October 9, 2017
• Est. primary completion date: October 2, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Be a male or female aged 18 to 55 years, inclusive.

• Have a body mass index (BMI) of = 18.5 to = 29.0 kg/m2 at Screening.

• Be healthy overall with no clinically significant medical abnormalities, as determined by the Investigator through evaluation of the subject's medical history and Screening vital signs, ECG, physical examination, and laboratory assessments.

• Applicable to Japanese Subjects Only: Japanese subjects must have been born in Japan, have both parents and all grandparents of Japanese origin, and not have lived outside of Japan for more than 5 years with no significant changes in lifestyle, including diet, since leaving Japan.

• Applicable to Non-Asian Subjects Only: Non-Asian subjects must have both parents and all grandparents of Non-Asian origin.

Exclusion Criteria:

• Have undergone any major surgical procedure within the 3 months prior to Screening.

• Test positive at Screening for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), or human immunodeficiency virus (HIV).

• Have a Screening systolic blood pressure (BP) reading of > 140 mmHg (> 150 mmHg in subjects > 45 years of age) OR a diastolic BP reading of > 90 mmHg after 5 minutes of supine rest.

• Have any of the following cardiac risk factors:

1. Be taking any medication with a known effect of QT interval prolongation (see list of medications in Appendix 1)

2. Have a cardiac pacemaker

3. Demonstrate on either the Screening ECG or the baseline ECG any evidence of atrial fibrillation, atrial flutter, complete right or left bundle branch block, or Wolff-Parkinson-White syndrome

4. Demonstrate on the Screening ECG any morphology that renders measurement of QT interval imprecise (eg, neuromuscular artifact that cannot be readily eliminated, indistinct QRS onset, low-amplitude T wave, merged T and U waves, prominent U waves, arrhythmia)

• Have a history of a known risk factor for Torsade de Pointes, including any of the following:

1. Personal or family history of congenital long QT syndrome, Brugada syndrome, or sudden death

2. Unexplained syncope

3. Heart failure

4. Myocardial infarction

5. Angina

6. Certain clinically significant laboratory assessment findings, including hypokalemia, hypercalcemia, or hypomagnesemia

• Have had, including by voluntary donation, > 400 mL of blood collected within the 3 months prior to Screening.

• Have taken within the 14 days prior to study drug dosing any prescription medication, over-the counter medication, or nonprescription preparation—including vitamins, minerals, phytotherapeutic/herbal/plant-derived preparations, or grapefruit juice—unless deemed acceptable by the Investigator OR have taken within the 28 days prior to study drug dosing any restricted product known to strongly induce CYP3A4 metabolism (eg, St. John's Wort).

• Have participated in another clinical research study within the 3 months prior to Screening.

Related Conditions & MeSH terms

• Healthy
• Japanese
• Non-Asian

Intervention

Drug:
• AG-348
50 mg single-dose
• AG-348
5 mg single-dose
• AG-348
200 mg single-dose

Locations

Country	Name	City	State
United States	West Coast Clinical Trial (WCCT) Global, Inc.	Cypress	California

Sponsors (1)

Lead Sponsor	Collaborator
Agios Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC	AG-348 Area Under the Curve	Pharmacokinetic sampling for AG-348 will be taken for 72 hours (4 days) after single dose
Primary	Cmax	AG-348 Maximum Plasma Concentration	Pharmacokinetic sampling for AG-348 will be taken for 72 hours (4 days) after single dose
Secondary	Incidence of Adverse Events	Assessment of adverse events	10 (± 1) days after single-dose of AG-348
Secondary	QTc interval	QTc interval measurements	Change in QTc from baseline will be presented by race and by cohort